Pulmonary Hypertension News and Research

RSS

Pulmonary arterial hypertension (PAH) is a condition involving high blood pressure and structural changes in the walls of the pulmonary arteries, which are the blood vessels that connect the right side of the heart to the lungs. Affecting people of all ages and ethnic backgrounds - but most commonly found in young women of child-bearing years - the disease has historically been chronic and incurable, with a poor survival rate. PAH is often not diagnosed in a timely manner because its early symptoms can be confused with those of many other pulmonary and respiratory conditions. Symptoms include shortness of breath, extreme fatigue, dizziness, fainting, swollen ankles and legs and chest pain (especially during physical activity). With proper diagnosis, there are currently several therapies to alleviate symptoms and improve quality of life for PAH patients. The key is to find a PAH specialist and pursue immediate treatment.

Johns Hopkins researchers identify human resistin as a key driver of inflammation

Researchers at Johns Hopkins Medicine have uncovered a critical biological mechanism that helps explain how inflammation is triggered and sustained in a wide range of diseases-highlighting a promising avenue for future therapeutic development.

9 Sep 2026

Blocking a naturally occurring molecule reverses deadly lung disease in preclinical models

Researchers blocked a naturally occurring molecule to reverse pulmonary arterial hypertension in preclinical models, a finding that could point to a new treatment approach for people with a rare and often fatal lung disease.

2 Sep 2026

New study makes progress in understanding the mechanisms behind severity of HFpEF

Approximately 3 million people in the United States are living with a condition called heart failure with preserved ejection fraction, or HFpEF.

24 Aug 2026

Qureight expands with addition of second site, to accommodate rapid growth and ongoing development of chest Foundation Model

Qureight, an end-to-end imaging company that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced the opening of its new office space in London, UK.

From Qureight 19 Aug 2026

Qureight closes $20 million Series B financing

From Qureight 30 Jul 2026

Study links COVID-19 to higher sleep apnea risk years after infection

Researchers analyzed more than 910,000 adults and found that SARS-CoV-2 infection was associated with a higher adjusted risk of new-onset obstructive sleep apnea up to 4.5 years later. The association appeared in both hospitalized and non-hospitalized COVID-19 patients, supporting targeted screening in higher-risk post-COVID groups while highlighting the need for objective sleep testing.

24 Jun 2026

Seven-second X-ray scan detects severe pulmonary valve regurgitation with high accuracy

Researchers at Kyushu University have developed a simple, rapid, and low-radiation X-ray technique that can evaluate the severity of a heart condition known as pulmonary valve regurgitation-a common and clinically significant complication after surgical repair of a congenital heart defect known as Tetralogy of Fallot.

4 Jun 2026

Qureight establishes Scientific Advisory Board focused on pulmonary hypertension

Qureight, an end-to-end imaging CRO that provides enterprise-grade imaging and precision endpoints for clinical trials with a focus on lung and heart disease, today announced it has established a Scientific Advisory Board (SAB) focused on pulmonary hypertension (PH).

From Qureight 11 May 2026

Transcatheter valve-in-valve procedure improves short-term outcomes in high-risk patients

In patients with a poorly functioning bioprosthetic mitral valve in the heart, a minimally invasive procedure to insert a new valve was associated with a lower rate of death or disabling stroke within one year, compared with patients who underwent standard repeat mitral valve replacement surgery, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

New drug sotatercept shows benefit in CpcPH-HFpEF patients

Patients who have heart failure with preserved ejection fraction (HFpEF) and high blood pressure in the lungs (pulmonary hypertension) experienced significant improvements in blood pressure and vascular health after taking the drug sotatercept, according to a study presented at the American College of Cardiology's Annual Scientific Session (ACC.26).

29 Mar 2026

Viagra ingredient improves symptoms in patients with Leigh syndrome

Sildenafil – an active ingredient also marketed under the name of Viagra – improves symptoms in patients with Leigh syndrome.

11 Mar 2026

New guidelines outline comprehensive care for acute pulmonary embolism

Early detection and prompt treatment of acute pulmonary embolism (PE), a sudden and potentially life-threatening blood clot that blocks arteries in the lungs, is critical.

19 Feb 2026

Redefining cardiovascular care for women

Cardiovascular disease (CVD) remains the leading cause of death for women across the globe, yet significant progress has been made in prevention, diagnosis and management thanks to more sex-specific research, as noted in a special Go Red for Women issue of Circulation, the American Heart Association's flagship, peer-reviewed scientific journal, published today.

17 Feb 2026

Beta arrestin 1 emerges as key driver of pulmonary hypertension

Researchers have uncovered the pivotal role of a previously overlooked protein in the development of the serious illness.

10 Feb 2026

Genetic signals reveal why erectile dysfunction develops and who is most at risk

This multi-ancestry genomic study identifies key genetic loci underlying erectile dysfunction and shows that ED risk is shaped by both cardiometabolic and substance use–related genetic pathways. Using EHR-linked data, the researchers uncover SIM1-related mechanisms, modest PRS performance, and bidirectional genetic links with obesity, diabetes, and addiction traits.

25 Nov 2025

Expert panel recommends new antibiotic strategies for resistant Bordetella pertussis

Pertussis, or whooping cough, remains a highly contagious respiratory infection caused by Bordetella pertussis. Despite inclusion of pertussis vaccines in immunization programs since the 1970s, outbreaks have re-emerged globally due to waning immunity and bacterial evolution.

19 Nov 2025

Exploring m6A RNA modification as a therapeutic target in cardiovascular disorders

Emerging research highlights the transformative potential of m6A RNA modification in the diagnosis and treatment of cardiovascular diseases (CVDs).

14 Nov 2025

Qureight Vascul8 model for pulmonary vascular disorders validated in peer-reviewed study, offering potential to improve treatment options and patient outcomes following surgery

Qureight, a techbio company advancing the understanding of lung and heart disease through application of its AI-powered imaging and clinical data curation platform, today announced the publication of a peer-reviewed study validating its Vascul8™ model for pulmonary vascular disorders, in the American Journal of Respiratory Cell and Molecular Biology.

27 Oct 2025

Sotatercept shows strong benefits for newly diagnosed pulmonary hypertension patients

Prescribing the biologic drug sotatercept alongside standard treatment for the most severe form of pulmonary hypertension significantly reduces the likelihood of worsening disease when added within the first year after diagnosis, according to a study published in the New England Journal of Medicine.

30 Sep 2025

electronRx to launch pDx app for remote chronic respiratory disease management

electronRx, a leading digital medicine and biomarker company driving healthcare through pulmonary innovation, today announced that it will launch pDx at HLTH 2025.

18 Sep 2025